WallStSmart

Delcath Systems Inc (DCTH)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 24099% more annual revenue ($20.63B vs $85.23M). GEHC leads profitability with a 10.1% profit margin vs 3.2%. DCTH appears more attractively valued with a PEG of 1.60. GEHC earns a higher WallStSmart Score of 60/100 (C+).

DCTH

Hold

44

out of 100

Grade: D

Growth: 7.3Profit: 3.5Value: 4.7Quality: 5.0

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DCTHSignificantly Overvalued (-1879.2%)

Margin of Safety

-1879.2%

Fair Value

$0.48

Current Price

$8.98

$8.50 premium

UndervaluedFair: $0.48Overvalued
GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DCTH2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
37.3%10/10

Revenue surging 37.3% year-over-year

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

DCTH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Market CapQuality
$320.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.0%3/10

ROE of 3.0% — below average capital efficiency

Profit MarginProfitability
3.2%3/10

3.2% margin — thin

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DCTH

The strongest argument for DCTH centers on Revenue Growth, Price/Book. Revenue growth of 37.3% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : DCTH

The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 129.6x leaves little room for execution misses. Thin 3.2% margins leave little buffer for downturns.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

DCTH profiles as a hypergrowth stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

DCTH is growing revenue faster at 37.3% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Delcath Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?